- $373.37m
- $265.57m
Brief: Rezolute Announces Alignment With FDA On Streamlined Design For Ongoing Phase 3 Trial Of Ersodetug In Tumor Hyperinsulinism
Brief: Rezolute Announces Alignment With FDA On Streamlined Design For Ongoing Phase 3 Trial Of Ersodetug In Tumor Hyperinsulinism
Brief: Rezolute Announces Completion Of Enrollment In The Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism
U.S. RESEARCH ROUNDUP-Fair Issac, First Solar, UnitedHealth
Rezolute Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Rezolute Q3 EPS USD -0.27
Rezolute Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Rezolute Announces Pricing Of Offering Of $90 Million Of Common Stock And Pre-Funded Warrants
Brief: Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
Rezolute Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Rezolute Q2 EPS USD -0.22
Rezolute Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Brief: Rezolute Receives Breakthrough Therapy Designation From FDA For Ersodetug In The Treatment Of Hypoglycemia Due To Congenital Hyperinsulinism
Rezolute Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Rezolute Q1 EPS USD -0.22
U.S. RESEARCH ROUNDUP-Cigna, Marriott, Ralph Lauren
Brief: Rezolute Q4 EPS USD -0.44
U.S. RESEARCH ROUNDUP-Apple, Fedex, Vaxcyte